Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

SELLAS Life Sciences Group, Inc. (SLS)

3.25   -0.15 (-4.41%) 01-27 16:00
Open: 3.43 Pre. Close: 3.4
High: 3.43 Low: 3.17
Volume: 183,360 Market Cap: 67(M)

Technical analysis

as of: 2023-01-27 4:48:00 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 4.18     One year: 4.88
Support: Support1: 2.66    Support2: 2.09
Resistance: Resistance1: 3.57    Resistance2: 4.18
Pivot: 3.07
Moving Average: MA(5): 3.38     MA(20): 2.93
MA(100): 2.79     MA(250): 3.36
MACD: MACD(12,26): 0.2     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 78     %D(3): 83.3
RSI: RSI(14): 59.3
52-week: High: 7.4  Low: 1.76
Average Vol(K): 3-Month: 285 (K)  10-Days: 203 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SLS ] has closed below upper band by 34.6%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.43 - 3.46 3.46 - 3.47
Low: 3.12 - 3.15 3.15 - 3.17
Close: 3.22 - 3.25 3.25 - 3.28

Company Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Headline News

Sun, 29 Jan 2023
SLS Rocket Exceeds Expectations, Preparations Commence for ... - autoevolution

Sat, 28 Jan 2023
NASA's Artemis Aces Performance Tests, Preparing to Support Crewed Mission | Weather.com - The Weather Channel

Fri, 27 Jan 2023
NASA’s ‘Mega Moon Rocket’ aced first flight and is ready for crewed Artemis II launch - TechCrunch

Fri, 27 Jan 2023
Data from SLS Flight Prepares NASA for Future Artemis Missions – Artemis - NASA Blogs

Fri, 27 Jan 2023
Data from First SLS Flight to Prepare NASA for Future Artemis Missions - NASA

Fri, 27 Jan 2023
SLS announces revised 2nd Qtr. Honor Roll – WRBI Radio - Country 103.9 WRBI

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 21 (M)
% Held by Insiders 2.034e+007 (%)
% Held by Institutions 0 (%)
Shares Short 1,150 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 842.2
Return on Equity (ttm) -55.6
Qtrly Rev. Growth 1e+006
Gross Profit (p.s.) 0
Sales Per Share -91.59
EBITDA (p.s.) 3.42593e+006
Qtrly Earnings Growth -2.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -24 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 11.5

Stock Dividends

Dividend 0
Forward Dividend 1.23e+006
Dividend Yield 0%
Dividend Pay Date 2019-11-07
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.